Evidence map›Paper›PMID 42621910›Full record

ArticleACS medicinal chemistry letters2026

Development of 2‑Methyl-5-phenylpyrrolidine-Based ST2 Inhibitors for Neuroinflammatory Conditions.

Xinrui Yuan, Eun Bee Cho, Amol D Patil, Md Aktaruzzaman, Andhavaram Ramaraju, Chenyao Jiang, Meilin Wang, Miao He, Aaron Robida, Bo Wen and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xinrui YuanDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Eun Bee ChoDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Amol D PatilDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.ORCID https://orcid.org/0000-0003-4269-228X
Md AktaruzzamanDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.ORCID https://orcid.org/0000-0003-1570-3588
Andhavaram RamarajuDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Chenyao JiangDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Meilin WangDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Miao HeDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Aaron RobidaDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Bo WenDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Duxin SunDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Jason C RechDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Jianxiong JiangDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.ORCID https://orcid.org/0000-0003-3955-8928
Chao-Yie YangDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.ORCID https://orcid.org/0000-0002-5445-0109

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
Inflammatory regulation of neurotrophin signaling in epileptogenesisR01NS100947 · NINDS · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI Jianxiong Jiang · 2018 to 2026
$2.8M
Development of first-in-class ST2 inhibitors for treating graft-versus-host diseaseR01HL141432 · NHLBI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI PACZESNY, SOPHIE, YANG, CHAO-YIE · 2019 to 2022
$2.6M
NCI NIH HHS P30 CA046592NHLBI NIH HHS R01 HL141432NINDS NIH HHS R01 NS100947
6 · The paper itself

Abstract

The cytokine receptor, ST2, is expressed in immune cells including type 2 T cells, microglia, and astrocytes. ST2 binds with IL-33 to activate the downstream NF-κB pathway. Besides the role of the ST2/IL-33 axis in the expansion of type 2 and regulatory T cells, it mediates the production of pro-inflammatory cytokines by a subset of myeloid cells under inflammatory conditions. Here, we designed and synthesized a new series of ST2 inhibitors by modifying the pyrrolidine core in our previous lead to develop

Indexed as

AstrocytesCentral nervous systemGraft versus host diseaseIL-1βIL-33Immune cellsMicrogliaNeuroinflammatory diseasesSmall-molecule inhibitorsST2

Identifiers

PMID42621910
PMCPMC13488090

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.